A longitudinal retrospective observational cohort study assessing the real-world utilization of poly(ADP-ribose) polymerase inhibitors (PARPi) in women with Ovarian cancer
Latest Information Update: 04 Jul 2022
At a glance
- Drugs Niraparib (Primary) ; Olaparib (Primary) ; Rucaparib (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 10 Nov 2021 New trial record
- 02 Nov 2021 Results published in the Advances in Therapy